Farex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Farex

Quick Facts

Property Description
Active ingredient Ibuprofen and Pseudoephedrine
Form Tablet or Caplet
Pharmacological class Combination of NSAID and Sympathomimetic Amine
Common use Symptomatic relief of fever, pain, and nasal congestion
Origin Synthetic

What is Farex?

What Type of Medication is Farex?

Farex is classified as a fixed-dose combination (FDC) synthetic drug designed for oral administration, typically presented as a tablet or caplet. This categorization reflects the product’s nature as a single medicinal entity containing two distinct active ingredients. The product is often positioned for the adult and adolescent patient group managing cold and flu symptoms.

The drug's pharmacological profile is defined by its two high-level classes: a Nonsteroidal anti-inflammatory drug (NSAID) and a sympathomimetic amine (or nasal decongestant). The combination approach is clinically recognized for its utility in targeting combined symptoms where a single agent may be insufficient.

Composition and Pharmaceutical Form

The core of Farex is the blend of the active ingredients, Ibuprofen and Pseudoephedrine hydrochloride. Ibuprofen functions as the anti-inflammatory and analgesic component, while Pseudoephedrine is the decongestant. The formulation of these two synthetic substances together is supported by evidence demonstrating the efficacy of such combinations for managing combined symptoms. These ingredients are formulated alongside solid excipients necessary to create the final, stable oral dosage form.

General Purpose of the Combination

The general therapeutic purpose of this fixed-dose combination is to provide simultaneous symptomatic relief from several key discomforts associated with upper respiratory issues, such as a severe cold. By uniting the actions of both ingredients, the medication is intended to relieve elevated fever, generalized body pain, and the pressure caused by nasal congestion. This dual functionality means the product aims to manage the most common, bothersome symptoms concurrently, offering a practical approach to achieving overall symptomatic improvement.

What side effects are possible with Farex?

Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety profile documented in the official regulatory labeling for the Ibuprofen and Pseudoephedrine combination product. The safety profile reflects the known risks associated with both the Nonsteroidal Anti-inflammatory Drug (NSAID) and the Sympathomimetic Amine components.

Regulatory Classification of Adverse Reactions

Side effects are classified in official documents according to their frequency and the system they affect.

Classification Examples of Reactions
Common Gastrointestinal disturbances (e.g., dyspepsia, nausea), nervousness, insomnia, headache, dizziness.
Uncommon Hypersensitivity reactions (e.g., pruritus, urticaria), acute psychiatric disturbances.
Rare Severe gastrointestinal bleeding or ulceration, hepatic dysfunction.

Serious Adverse Reactions

Official labeling documents serious adverse reactions that, while rare, are clinically significant. These include life-threatening gastrointestinal bleeding and perforation, and major cardiovascular thrombotic events (such as myocardial infarction or stroke), particularly with long-term, high-dose exposure. Severe hypersensitivity events and cases of severe hypertension are also documented safety concerns.

Population-Specific Safety Considerations

The regulatory profile highlights specific cautions for certain groups. Older adults have an increased documented risk of serious gastrointestinal and cardiovascular adverse events. Safety constraints are also detailed for individuals with pre-existing conditions, including severe or uncontrolled hypertension, coronary artery disease, severe hepatic or renal impairment, and a history of NSAID-related GI bleeding.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The overdose profile for Farex is defined by the combined risks of its two active components, requiring management that is strictly symptomatic and supportive, as no specific antidote is documented in regulatory labeling.

Domain Official Regulatory Statements
Documented Manifestations Overdose presentations include severe gastrointestinal effects (vomiting, abdominal pain, hemorrhage), and Central Nervous System symptoms such as severe drowsiness, agitation, dizziness, incoherence, and the potential for convulsions and coma. Cardiovascular instability may involve irregular heartbeat and blood pressure changes.
Severe Outcomes Life-threatening outcomes include severe gastrointestinal hemorrhage, acute renal failure, metabolic acidosis, and respiratory depression. These severe events define the classification of a high-risk overdose scenario.
Population Risk Factors Increased risk of severe cardiorenal and gastrointestinal outcomes is explicitly noted for the elderly population and individuals with pre-existing cardiovascular or renal impairment.

Emergency-Response Mandates

  • Seek emergency medical attention immediately upon any known or suspected overdose.
  • Contact a Certified Poison Control Center right away for guidance.

Management requires continuous monitoring of vital signs and ECG, and may involve advanced support procedures like airway management and intravenous fluid administration.

Therapeutic Uses of Farex

Farex is commonly used across conditions presenting with acute episodes, particularly those characterized by periods of heightened symptoms, such as the common cold and influenza. The medication is relevant in clinical settings that involve acute or disruptive symptom patterns, and is commonly used to help with two main areas of patient discomfort. The combination is specifically used to help with symptoms related to headache, fever, sinus pressure, nasal congestion, and minor body aches.


Relief for Systemic Pain and Elevated Body Temperature

This domain covers symptoms related to systemic imbalance, such as generalized body aches, muscular pain, headache, and elevated body temperature (fever). The medication is applied in contexts marked by increased discomfort or tension, and helps support patients during difficult episodes by easing distress and contributing to improved day-to-day comfort.

“It is relevant in contexts involving heightened systemic burden, when multiple symptoms occur together.”

Easing Nasal and Sinus Obstruction

The medication is relevant for managing symptoms that interfere with daily functioning, such as a stuffy nose or nasal congestion, and the associated sinus pressure or headache. Used when symptoms become more disruptive during flare-ups, it provides support that helps ease the overall symptom burden linked to nasal obstruction. This assists with maintaining functional stability by managing the congestion.


Quick Fact: Symptom Management Contexts Domain Symptoms Addressed
Systemic Discomfort Fever, headache, body aches
Upper Respiratory Nasal congestion, sinus pressure
Patient Benefit Contributes to easing the overall symptom load

Regulatory References

  1. U.S. National Library of Medicine DailyMed

Eligibility and Restrictions for Use

Farex, a combination of Ibuprofen and Pseudoephedrine, is subject to strict eligibility rules set by regulatory authorities, which define who can and cannot use the medicine.

Age-Related Eligibility

The product is approved for use in Adults and Adolescents aged 12 years and older. It is contraindicated or not recommended for children under 12 years of age. Older adults should use with caution due to increased susceptibility to risks, which may necessitate lower dosing, though no geriatric-specific problems limit its usefulness.

Absolute Contraindications (Must Not Use)

Farex is contraindicated in patients with a history of hypersensitivity to Ibuprofen, Pseudoephedrine, or other NSAIDs (like aspirin). It must not be used by those with severe or uncontrolled heart conditions, including severe heart failure, severe hypertension, or severe coronary artery disease. Non-eligibility also applies to patients with active or recurrent peptic ulcer/haemorrhage, or severe renal or severe hepatic insufficiency.

Pregnancy and Lactation Status

Use is contraindicated during the third trimester of pregnancy. The medicine is generally not recommended during the first two trimesters, or for women who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of this Ibuprofen and Pseudoephedrine combination around two primary risk categories: interactions leading to increased pressor effects and those increasing the risk of bleeding or toxicity from other drugs.

Contraindicated Combinations

Category Regulatory Interaction Classification
Monoamine Oxidase Inhibitors (MAOIs) Strictly Contraindicated due to risk of hypertensive crisis from Pseudoephedrine. Must not be used within 14 days of stopping MAOI therapy.
Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Contraindicated due to significantly increased risk of gastrointestinal bleeding and ulceration from the Ibuprofen component.
Aspirin (High Dose) Contraindicated for analgesic/antipyretic use (doses >100 mg/day) due to increased gastrointestinal risk.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Co-administration with several medicinal product categories is officially documented to lead to clinically significant interaction outcomes:

  • Anticoagulants and Antiplatelet Agents: Regulatory documents note an increased risk of gastrointestinal bleeding when combined with the Ibuprofen component. This includes agents such as Warfarin and Selective Serotonin Reuptake Inhibitors (SSRIs).
  • Antihypertensives: The combination is documented to reduce the efficacy of many antihypertensive agents, including ACE inhibitors and Beta-blockers.
  • Drugs with Reduced Clearance: The Ibuprofen component is documented to increase plasma concentrations of certain drugs by reducing their renal clearance, notably Lithium and Methotrexate.
  • Other Sympathomimetics: Use with other decongestants or sympathomimetic amines is not recommended due to additive cardiovascular adverse effects.

Substance and Population-Specific Restrictions

Alcohol must be avoided during treatment, as official regulatory sources document that this increases the risk of gastrointestinal bleeding. Furthermore, interaction risks related to gastrointestinal bleeding and renal impairment are noted in official labeling as generally higher for elderly patients.

Mechanism of Action

How Farex Works: Mechanism of Action

Farex is a fixed-dose combination drug whose physiological effects emerge from two distinct, yet complementary, mechanistic domains that modulate key biological pathways.


Enzyme Inhibition in Prostanoid Synthesis

The Ibuprofen component acts by non-selectively inhibiting the Cyclooxygenase (COX-1 and COX-2) enzymes. This molecular action blocks the Arachidonic Acid Cascade, thereby suppressing the synthesis of pro-inflammatory mediators like Prostaglandin E2 ( PGE2). The resulting cascade leads to the modulation of the hypothalamic temperature set-point and reduces the chemical modulation threshold of peripheral nociceptors.


Alpha-Adrenergic Agonism on Vascular Tone

The Pseudoephedrine component is a sympathomimetic amine that engages the autonomic nervous system by acting as both a direct and indirect agonist on alpha-adrenergic receptors (alpha-AR) found in the nasal mucosa vasculature. This interaction triggers local vasoconstriction. The resulting physiological effect is a mechanical reduction in blood flow and hydrostatic pressure, which reduces fluid extravasation and tissue volume in the upper respiratory passages.


Synergistic Modulation of Pathophysiological Responses

The final physiological effect is achieved through mechanistic synergy: Ibuprofen modulates systemic prostanoid-mediated signals, while Pseudoephedrine provides targeted modulation of local adrenergic-vascular dynamics. This combined action influences the downstream physiological effects of both chemical mediator release and fluid-driven tissue volume.

Dosage and Administration Information

How to Use Farex: Official Administration Guidelines

This section describes the standard administration of the combination product containing Ibuprofen (200 mg) and Pseudoephedrine HCl (30 mg).


Administration Scope

The approved method for administering this medication is the oral route only, typically involving swallowing a tablet, caplet, or liquid-filled capsule whole. No preparation or reconstitution is required for the standard dosage forms. The instruction permits taking the dose with food or milk to help mitigate potential gastrointestinal discomfort, a common high-level instruction associated with the Ibuprofen component.

Category Official Use Instruction
Standard Dosing One or two units (200 mg Ibuprofen / 30 mg Pseudoephedrine HCl) per dose.
Frequency Doses are repeated every 4 to 6 hours as required for acute symptoms.
Maximum Daily Limit Consumption must not exceed 6 units (1200 mg Ibuprofen / 180 mg Pseudoephedrine HCl) in any 24-hour period.
Age Restriction Approved for use in adults and adolescents 12 years of age and over.

Procedural Structure and Duration

The protocol defines the use of this fixed-dose combination as a short-term measure for acute, self-limiting conditions. The duration of use is constrained, meaning the medication should generally not be used for more than 7 days for pain or congestion, or more than 3 days for fever, unless explicitly directed otherwise. As an as-needed (PRN) medication, the instructions dictate that administration should only be resumed at the standard interval when symptoms return, always respecting the strict 24-hour maximum limit.

Recent Clinical Evidence

Research evidence / Overview of Studies for Farex

Evidence for Symptomatic Relief of the Common Cold and Flu

Research for the combination of ibuprofen and pseudoephedrine was evaluated primarily in short-term, randomized controlled trials (RCTs). These studies compared the combination product against a placebo or the individual active components. This approach was studied for its use in conditions associated with episodic manifestations of the common cold or influenza-like illness.

Studies focused on patient-reported outcomes describing perceived discomfort and the monitoring of overall symptom intensity over short time intervals. Studies reported measurements where participant-reported changes in global symptoms were monitored closely over the acute period. Evidence for this use has a coarse grading of High in the context of short-term symptom relief evaluation for adults and adolescents.


Research on Component-Specific Symptom Relief

This research examines the two primary domains of relief separately. Studies explored the anti-pain and anti-fever effects (outcomes of the ibuprofen component), monitoring physiological strain, such as changes in measured body temperature and scores for headache and body pain.

Research also examined outcomes describing episodic or acute changes in nasal congestion, stuffy nose, and sinus pressure (outcomes of the pseudoephedrine component). Data document patterns measured during temporary physiological imbalance in the nasal passages.


What Research Shows is Still Uncertain

The overall evidence highlights what is known and what is still uncertain. The typical follow-up durations for the key efficacy trials were limited, usually spanning only a few days to about a week. Consequently, there is limited information for long-term outcomes or the consequences of using this combination beyond the typical short, acute course.

The majority of evidence is based on studies of adults and adolescents. Few data are available evaluating the combination's outcomes in younger children (under 12 years of age). Furthermore, heterogeneity in trial designs means evidence consistency varies across studies, and the data is less amenable to combined analysis. The research provides context but not individual predictions.

Key Studies & References Assessment of the use of ibuprofen and pseudoephedrine for symptomatic relief of acute rhinosinusitis and rhinitis

Frequently Asked Questions (FAQ)

Common questions about Farex (FAQ)


Q: How quickly does Farex typically start working?

Clinical evidence and official monograph summaries indicate that the symptomatic relief provided by this combination product begins relatively quickly. Clinical studies have observed that some participants reported feeling relief from their symptoms starting within 30 minutes after taking the medication.

Q: Is Farex considered a controlled substance?

The Pseudoephedrine component is a chemical precursor that is subject to specific government regulations. Because of this precursor status, the sale and purchase of the product, even over-the-counter, are subject to mandatory tracking and restriction laws under government acts.

Q: What happens if I miss a Farex dose?

Official guidance indicates that if a dose is forgotten, the general instruction is to take it as soon as the patient remembers, unless it is already close to the time for the next scheduled dose. If so, the patient information advises skipping the missed dose and proceeding with the regular schedule, ensuring no extra or double doses are taken.

Q: Is it true that Farex can cause drowsiness?

Yes, official regulatory labeling indicates that drowsiness, or sleepiness, is a possible side effect of this medication. This effect is listed alongside other central nervous system effects such as dizziness and insomnia.

Q: Are there any specific foods to avoid when taking Farex?

Official product information notes that the use of alcohol during treatment is advised against, as this combination increases the risk of gastrointestinal bleeding. To help prevent stomach upset, the instructions permit taking the dose with food or milk, but no other specific foods are generally restricted in regulatory documents.

Q: Can Farex affect my ability to drive or operate machinery?

The official labeling lists side effects such as dizziness, drowsiness, and nervousness, which may temporarily affect mental alertness. The presence of these side effects means that caution is necessary before engaging in activities that require mental alertness, such as driving or operating machinery.

Q: Does Farex have a 'black box' warning?

Official regulatory labeling for this combination product includes strong safety warnings related to the risks of the Ibuprofen component. These major cautions, such as the warning about the potential for heart attack, stroke, and stomach bleeding, are prominent safety statements required by regulatory bodies.

Q: Are there long-term side effects associated with Farex use?

Official labeling indicates that this product is intended for short-term use only. The regulatory warning indicates that the risk of serious side effects, such as cardiovascular thrombotic events, increases if the medication is used for a prolonged period or at doses higher than recommended.

Q: Does Farex cause mood swings or emotional changes?

The sympathomimetic component of the drug can affect the central nervous system. Official documentation notes that uncommon side effects can include excitability, nervousness, and anxiety. The documented effects, such as excitability and anxiety, are consistent with general terms users may associate with emotional changes.

Q: Are there any non-prescription supplements that interact with Farex?

Official regulatory warnings suggest that users discuss all non-prescription items with a healthcare professional. This is because the safety and effects of combining supplements or complementary medicines with pseudoephedrine are generally not fully tested or documented in clinical trials.

Q: What should I do if a side effect seems serious?

Regulatory documents state that if serious symptoms occur, such as signs of stomach bleeding (bloody or black stools, vomiting blood) or symptoms suggesting a heart or stroke event (chest pain, slurred speech), use must be stopped immediately. The official labeling indicates that these conditions warrant immediately stopping use and seeking emergency medical help.

Q: Is Farex safe to stop taking suddenly?

The regulatory monograph notes that if the product is used for an extended period or at doses higher than recommended, the pseudoephedrine component may carry a risk of physical dependence. The patient information leaflet generally recommends that if the product has been used for a long time, the cessation of use should be managed gradually, as advised by a healthcare professional.

Q: Does Farex require any special monitoring or regular testing?

Official patient information indicates that some patients may require special monitoring, especially those with pre-existing conditions. For example, official warnings note that individuals with conditions like diabetes may require more frequent blood sugar monitoring while using the medication.

Q: Is Farex known to cause dependence?

Official regulatory documentation acknowledges that physical dependence is possible due to the pseudoephedrine component of the drug. This risk is typically associated with using the medication for long periods or at doses greater than the recommended amount, and is noted on the official patient information leaflet.

Q: What happens when Farex is taken with certain vitamins?

Explicit interaction data for individual vitamins is not always documented in the official labeling. However, regulatory guidance strongly advises patients to disclose all vitamins, supplements, and other over-the-counter products to their healthcare provider.

Q: Does Farex need to be taken at a specific time of day?

The administration protocol dictates taking a dose every four to six hours as needed for symptoms. Official safety information, however, notes that insomnia (trouble sleeping) is a common side effect of the product. Due to this potential effect, doses are often taken with consideration for the patient's sleep schedule.

Q: Are there any known drug-herb interactions with Farex?

Official patient guidance suggests that there is a lack of scientific data concerning the safety of combining herbal remedies with the active ingredients in this medication. As a result, it is advised to check with a doctor or pharmacist for information on potential interactions before combining them.

Q: What are the signs of an allergic reaction to Farex?

According to the official Drug Facts warnings, signs of a severe allergic reaction may include hives, facial swelling, difficulty breathing (wheezing), and blistering of the skin. If any of these signs appear, the regulatory documents state that use must be stopped immediately, and prompt medical attention is advised.

Q: Can Farex be taken on an empty stomach?

The regulatory instructions permit taking the dose with food or milk to help reduce the chance of experiencing gastrointestinal discomfort. However, the label information highlights that taking the dose with food or milk helps reduce the potential for gastrointestinal discomfort associated with the ibuprofen component.

Q: Does Farex cause changes in appetite?

Official regulatory documentation for the product lists a loss of appetite as a possible side effect. This is one of several gastrointestinal disturbances that may occur while taking the medication.

Q: Is Farex known to interact with caffeine?

The regulatory summary advises caution when combining this medication with caffeine or caffeine-containing products. Both the decongestant component and caffeine are known to stimulate the central nervous system and can cause increases in heart rate and blood pressure, potentially creating additive effects.

How should Farex be stored and disposed of?

Storage and Disposal Requirements for Farex

Farex is regulated as an infant food, and its storage requirements focus on maintaining nutrient stability and preventing bacterial contamination as outlined in government food safety guidelines.

Storage and Stability

Condition Requirement (Official Statement)
Unopened Storage Store containers in a cool, dry, indoor location, away from freezers or direct heat. Do not use if the container is damaged.
Opened Stability Opened powdered product must be kept tightly closed to protect from moisture and should be used within one month.
Prepared Product Prepared cereal must be used within two hours or refrigerated and used within 24 hours.

Disposal

Uneaten product left in the feeding bowl must be discarded immediately after a meal to prevent bacterial growth. Expired or unused powdered product should be mixed with an undesirable substance (such as dirt) and sealed in a bag before disposal in household trash, following general governmental guidance for waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Farex found in:

A-Z Index: